Kenneth Zuerblis
Director/Board Member at RESVERLOGIX CORP.
Net worth: 44 077 $ as of 2024-03-30
Profile
Kenneth J.
Zuerblis is currently serving as an Independent Director at Resverlogix Corp., Zenith Capital Corp.
(Alberta), and Lirum Therapeutics, Inc. He started his current positions in 2010, 2013, and 2023 respectively.
In his former roles, Mr. Zuerblis worked as an Independent Director at Immunomedics, Inc. from 2010 to 2012, as a Director at Stemline Therapeutics, Inc. from 2012 to 2020, and as a Director at XTL Biopharmaceuticals Ltd.
in 2009.
He also served as a Director at New Jersey Technology Council and held the position of Chief Financial Officer, Treasurer & Executive VP at Savient Pharmaceuticals, Inc. from 2011 to 2012.
Additionally, he worked as the Chief Financial Officer at Enzon Pharmaceuticals, Inc. from 1994 to 2005 and at ImClone LLC in 2009.
Mr. Zuerblis started his career as a Controller at KPMG LLP in 1991.
Mr. Zuerblis obtained his undergraduate degree from Seton Hall University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ZENITH CAPITAL CORP.
0.17% | 2024-04-14 | 263,870 ( 0.17% ) | 39 581 $ | 2024-03-30 |
RESVERLOGIX CORP.
0.04% | 2024-01-01 | 107,062 ( 0.04% ) | 4 497 $ | 2024-03-30 |
Kenneth Zuerblis active positions
| Companies | Position | Start |
|---|---|---|
| RESVERLOGIX CORP. | Director/Board Member | 2010-09-28 |
| ZENITH CAPITAL CORP. | Director/Board Member | 2013-04-09 |
Lirum Therapeutics, Inc.
 Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Director/Board Member | 2023-04-30 |
Former positions of Kenneth Zuerblis
| Companies | Position | End |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Director/Board Member | 2020-06-09 |
| SAVIENT PHARMACEUTICALS INC | Director of Finance/CFO | 2012-04-30 |
| IMMUNOMEDICS, INC. | Director/Board Member | 2012-03-07 |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Director of Finance/CFO | 2008-12-31 |
| XTL BIOPHARMACEUTICALS LTD. | Director/Board Member | 2008-12-31 |
Training of Kenneth Zuerblis
| Seton Hall University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| ENZON PHARMACEUTICALS, INC. | Health Technology |
| RESVERLOGIX CORP. | Health Technology |
| ZENITH CAPITAL CORP. | Health Technology |
| XTL BIOPHARMACEUTICALS LTD. | Health Technology |
 | Health Technology |
| Private companies | 6 |
|---|---|
Savient Pharmaceuticals, Inc.
 Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ. | Health Technology |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
KPMG LLP
 KPMG LLP Miscellaneous Commercial ServicesCommercial Services KPMG LLP engages in the provision of audit, tax, and advisory services. It serves the banking and capital markets, building, construction and real estate, consumer and retail, energy, natural resources and chemicals, financial services, government and public sector, healthcare and life sciences, industrial manufacturing, insurance, media and entertainment, private equity, technology, telecommunications, and venture capital industries. The company was founded in 1987 and is headquartered in New York, NY. | Commercial Services |
New Jersey Technology Council
 New Jersey Technology Council Miscellaneous Commercial ServicesCommercial Services New Jersey Technology Council provides business development, education and advocacy services. It serves communications, e-business, multimedia, consumer technologies, manufacturing, engineering and energy sectors. The company was founded in 1996 and is headquartered in New Brunswick, NJ. | Commercial Services |
- Stock Market
- Insiders
- Kenneth Zuerblis
